Camrelizumab in Combination With Neoadjuvant Chemotherapy
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteosarcoma
Conditions
Osteosarcoma
Trial Timeline
Dec 26, 2019 → Sep 16, 2023
NCT ID
NCT04294511About Camrelizumab in Combination With Neoadjuvant Chemotherapy
Camrelizumab in Combination With Neoadjuvant Chemotherapy is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Osteosarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04294511. Target conditions include Osteosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04606108 | Phase 2 | UNKNOWN |
| NCT04294511 | Phase 2 | UNKNOWN |
Competing Products
18 competing products in Osteosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azenosertib + Gemcitabine | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| Lenvatinib + Ifosfamide + Etoposide + Lenvatinib | Eisai | Phase 2 | 52 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Olaparib + Ceralasertib | AstraZeneca | Phase 2 | 52 |
| Saracatinib + Placebo | AstraZeneca | Phase 2 | 52 |
| robatumumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| pazopanib | Novartis | Phase 2 | 52 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Nivolumab + Azacitidine | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cisplatin liposomal | Insmed | Phase 1/2 | 38 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| Sm-EDTMP | Jazz Pharmaceuticals | Phase 2 | 49 |
| LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Lantheus Holdings | Phase 1/2 | 38 |
| REOLYSIN® | Oncolytics Biotech | Phase 2 | 44 |